Pinned post
Pomalyst, Darzalex, and Trelegy Ellipta account for $9.9 billion in annual Medicare spending, ranking among the highest-cost drugs in the program. Why are these drugs so expensive, and why has generic or biosimilar competition failed to materialize?
The answer lies in what we call the ‘Monopoly Extension Menu’—a set of overlapping schemes that pharmaceutical companies deploy to exploit the U.S. patent system in order to maintain market exclusivity.
reports.i-mak.org/monopoly-exten…
The answer lies in what we call the ‘Monopoly Extension Menu’—a set of overlapping schemes that pharmaceutical companies deploy to exploit the U.S. patent system in order to maintain market exclusivity.
reports.i-mak.org/monopoly-exten…
reports.i-mak.org The Monopoly Extension Menu | I-MAK High prescription drug prices in the United States are often explained as an unavoidable consequence of investment in biomedical progress. Yet across therapeutic areas, delayed competition more often... 
